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Abstract The multi-site phosphorylation of the protein kinase
C (PKC) superfamily plays an important role in the regulation of
these enzymes. One of the key phosphorylation sites required for
the activation of all PKC isoforms lies in the T-loop of the kinase
domain. Recent in vitro and transfection experiments indicate
that phosphorylation of this residue can be mediated by the 3-
phosphoinositide-dependent protein kinase-1 (PDK1). In this
study, we demonstrate that in embryonic stem (ES) cells lacking
PDK1 (PDK13/3 cells), the intracellular levels of endogenously
expressed PKCK, PKCLI, PKCQ, PKCN, PKCO, and PKC-
related kinase-1 (PRK1) are vastly reduced compared to control
ES cells (PDK1+/+ cells). The levels of PKCj and PRK2 protein
are only moderately reduced in the PDK13/3 ES cells. We
demonstrate that in contrast to PKCj expressed PDK1+/+ ES
cells, PKCj in ES cells lacking PDK1 is not phosphorylated at
its T-loop residue. This provides the first genetic evidence that
PKCj is a physiological substrate for PDK1. In contrast, PRK2
is still partially phosphorylated at its T-loop in PDK13/3 cells,
indicating the existence of a PDK1-independent mechanism for
the phosphorylation of PRK2 at this residue. ß 2000 Federa-
tion of European Biochemical Societies. Published by Elsevier
Science B.V. All rights reserved.
1. Introduction
Members of the AGC family of protein kinases include the
cAMP-dependent protein kinase (PKA), protein kinase B
(PKB) and protein kinase C (PKC) isoforms. These kinases
are activated by hormones and growth factors and mediate
many of the cellular responses that are controlled by these
agonists by phosphorylating key regulatory proteins. All
AGC kinase members require phosphorylation of a Thr or
Ser residue for activity that lies in a region of the kinase
domain termed the T-loop [1,2]. The amino acid sequence
immediately C-terminal to this site of phosphorylation is
highly conserved in all AGC kinases, indicating that it may
be phosphorylated by a common upstream protein kinase.
Consistent with this hypothesis, the 3-phosphoinositide-de-
pendent protein kinase-1 (PDK1) phosphorylates the T-loop
residue of many members of the AGC kinase family either in
vitro, or when PDK1 is overexpressed in cells [2^4].
To de¢ne the cellular roles of PDK1 in activating AGC
kinase members more rigorously, we have generated mouse
embryonic stem (ES) cells in which both copies of the
PDK1 gene have been disrupted to prevent the expression
of PDK1 [5]. Although these cells were viable, we found
that a number of AGC kinases activated by extracellular stim-
uli, namely PKB isoforms, p70 ribosomal S6 kinase (S6K1)
and p90 ribosomal S6 kinase (p90Rsk), were not activated by
agonists that activate these enzymes in wild type ES cells,
indicating that these kinases are physiological substrates for
PDK1. However, these studies also revealed that PDK1 is not
rate limiting for the phosphorylation and activation of all
AGC kinases, as PKA, mitogen- and stress-stimulated protein
kinase-1 and the AMP-dependent protein kinase were acti-
vated normally in ES cells de¢cient in PDK1 [5].
The PKC superfamily consists of 12 distinct members that
have been divided into four subfamilies [6]. The conventional
isoforms (PKCK, PKCL and PKCQ) are activated by diacyl-
glycerol and calcium, the novel isoforms (PKCN, PKCO,
PKCR and PKCa) are regulated only by diacylglycerol; while
the atypical isoforms (PKCj, PKCS and PKCV) and related
isoforms (PKC-related kinase-1 (PRK1) and PRK2) are not
regulated by diacylglycerol or calcium. Like other members of
the AGC family, PKC isoforms require phosphorylation of
their T-loop residue for activity, a reaction that can be medi-
ated by PDK1 in vitro or in transfection experiments [7^12].
In this study, we demonstrate that in ES cells lacking PDK1,
the levels of PKCK, PKCLI, PKCQ, PKCN, PKCO, and PRK1
are vastly reduced compared to control ES cells. Our data
con¢rm that PKCj is an in vivo substrate for PDK1, but
indicate the existence of a PDK1-independent mechanism
that may regulate T-loop phosphorylation of PRK2, as
PRK2 is still partially phosphorylated at its T-loop in ES cells
lacking PDK1.
2. Materials and methods
2.1. Materials
Protease inhibitor cocktail tablets were from Roche, microcystin-
LR, murine leukaemia inhibitory factor (ESGRO1), KnockOut1
Dulbecco’s modi¢ed Eagle’s medium, KnockOut serum replacement
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and other tissue culture reagents were from Life Technologies, prot-
amine-agarose was from Sigma, CH-Sepharose, HiTrap Q-Sepharose
column and the Mono S column were from Amersham Pharmacia
Biotech. The precast 4^12% and 3^8% gradient sodium dodecyl sul-
phate (SDS)^polyacrylamide gels were from Invitrogen. All the pep-
tides used in this study were synthesised by Dr G. Blomberg (Univer-
sity of Bristol, UK). Recombinant PKCK and PKCN were from
Panvera, whilst PKCL1, PKCL2, PKCQ, PKCN and PKCO were
from Upstate Biotechnology. Flag epitope-tagged PKCj and PRK2
were expressed by transient transfection in 293 cells as described pre-
viously [7].
2.2. Antibodies
The characterisation of the phospho-speci¢c antibody recognising
PRK2 phosphorylated at its T-loop (Thr816) termed T816-P and the
phospho-speci¢c antibody recognising PKCj phosphorylated at its
T-loop (Thr410), termed T410-P, has been described previously [7].
Antibodies recognising PRK2 and PKCj were raised in sheep against
the peptide KKVKPPFIPTIRGREDVSNFDDEFT (corresponding
to residues 927^951 of the human PRK2) and peptide TPDDEDAIK-
RIDQSEFEGFEYINIP (corresponding to residues 560^583 of the
mouse PKCj), respectively. The antibodies were a⁄nity-puri¢ed on
CH-Sepharose covalently coupled to the peptide antigen used to raise
the antibody, and are available from Upstate Biotechnology. The
antibodies recognising the following PKC isoforms were purchased
as indicated: PKCK (UBI, catalogue number 05-154), PKCL (Trans-
duction Laboratories, catalogue number P17720), PKCLI (Santa
Cruz, catalogue number Sc-209), PKCLII (Santa Cruz, catalogue
number Sc-210), PKCQ (Santa Cruz, catalogue number Sc-211),
PKCN (Santa Cruz, catalogue number Sc-213), PKCO (Transduction
Laboratories, catalogue number P14820) and PRK1 (Santa Cruz,
catalogue number SC-1842). Secondary antibodies coupled to horse-
radish peroxidase used for immunoblotting were from Pierce.
2.3. Bu¡er solutions
Bu¡er A: 50 mM Tris^HCl pH 7.5, 1 mM EGTA, 1 mM EDTA,
1% (by mass) Triton X-100, 1 mM sodium orthovanadate, 50 mM
sodium £uoride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 1 WM
microcystin-LR, 0.1% (by volume) L-mercaptoethanol and ‘complete’
proteinase inhibitor cocktail (one tablet per 25 ml Roche-Boehringer
Mannheim, Lewes, UK). Bu¡er B: 50 mM Tris^HCl pH 7.5, 1 mM
EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 50 mM sodium
£uoride, 5 mM sodium pyrophosphate, 0.27 M sucrose and 0.1% (by
volume) L-mercaptoethanol. Bu¡er C: 50 mM Tris^HCl pH 7.5,
0.1 mM EGTA, and 0.1% (by volume) L-mercaptoethanol. SDS sam-
ple bu¡er: 50 mM Tris^HCl pH 6.8, 2% (by mass) SDS, 10% (by
volume) glycerol and 1% (by volume) L-mercaptoethanol.
2.4. Cell Culture and lysis
PDK1+/+ and PDK13/3 ES cells were cultured to con£uence on
gelatinised 10 cm diameter dishes in KnockOut1 Dulbecco’s modi¢ed
Eagle’s medium supplemented with 10% KnockOut1 serum replace-
ment, 0.1 mM non-essential amino acids, antibiotics (100 U penicillin
G, 100 mg/ml streptomycin), 2 mM L-glutamine, 0.1 mM L-mercap-
toethanol and 1000 U/ml ESGRO1 (murine leukaemia inhibitory
factor to prevent di¡erentiation of the cells). Unless indicated other-
wise, the cells were then lysed in 0.5 ml of ice cold bu¡er A, and
centrifuged at 4‡C for 10 min at 16 000Ug. The supernatants were
frozen in liquid nitrogen and stored at 380‡C until use. Protein con-
centrations were determined by the Bradford method using bovine
serum albumin as a standard. Where indicated, cells were also lysed
in 0.5 ml of SDS sample bu¡er and the DNA was fragmented by
sonicating the lysates in a water-bath sonicator (Decon FS2006) for
15 min at maximum output. The lysates were passed through a 25GA
microlance3 needle (Becton Dickinson) 10 times and centrifuged at
room temperature for 10 min at 16 000Ug. The supernatant (10^20
Wl) was used for immunoblotting.
2.5. Puri¢cation of PKCj and PRK2 from ES cells on protamine-
agarose
Cell lysates (500 Wg of protein) were incubated with protamine-aga-
rose resin (10 Wl) previously equilibrated in bu¡er A, for 2 h at 4‡C on
a shaking platform. The beads were washed twice with bu¡er A con-
taining 0.5 M NaCl and twice with bu¡er C. The beads were imme-
diately resuspended in one volume of 2-fold concentrated SDS sample
bu¡er and subjected to SDS^polyacrylamide gel electrophoresis, fol-
lowed by immunoblotting with the indicated antibodies.
2.6. Puri¢cation of PRK2 and PKCj from ES cells on Mono Q and
Mono S Sepharose
Cell lysates (40 mg of protein) derived from PDK1+/+ and
PDK13/3 ES cells were applied to a HiTrap Q-Sepharose column
(5 ml) equilibrated in bu¡er B. The column was washed sequentially
with 15 ml of bu¡er B, bu¡er B containing 0.1 M NaCl, and bu¡er B
containing 0.4 M NaCl. Immunoblotting revealed that PRK2 and
PKCj were present in the 0.4 M eluate, which was dialysed in a
Slide-A-Lyzer (Pierce) for 2 h with two changes of bu¡er B and
then chromatographed on a 1 ml Mono S HR 5/5 column equilibrated
in bu¡er B. The column was washed with 10 ml of bu¡er B and then
developed with a 30 ml non-linear salt gradient to 1 M NaCl at a £ow
rate of 1 ml/min and fractions of 1 ml were collected. The non-linear
gradient was achieved by increasing the salt concentration from 0 to
0.1 M NaCl (fractions 1^8), 0.1^0.3 M NaCl (fractions 9^16), 0.3^
0.7 M NaCl (fractions 17^24), 0.7^1.0 M NaCl (fractions 25^27) and
1.0 M NaCl (fractions 28^30).
2.7. Immunoblotting
For blots of total ES cell lysate, 40 Wg of protein was used. For
blots of the protamine-agarose pulls down, 10 Wl of beads that had
been incubated with 500 Wg of cell lysate protein was used. For blots
of the Mono S column eluate, 30 Wl of each fraction was used. These
samples were subjected to SDS^polyacrylamide gel electrophoresis,
and transferred to nitrocellulose. For experiments in which PKC iso-
forms were being immunoblotted, the membranes were incubated in
50 mM Tris^HCl pH 7.5, 0.15 M NaCl, 0.5% (by volume) Tween
(TBS-Tween) and 10% (by mass) skimmed milk for 2 h at room
temperature in the presence of the indicated antibody concentrations:
PKCK (0.2 Wg/ml), PKCLI (0.4 Wg/ml), PKCLII (0.4 Wg/ml), PKCQ
(0.4 Wg/ml), PKCN (0.4 Wg/ml), PKCO (2.5 Wg/ml), PKCj (0.4 Wg/
ml), PRK1 (0.4 Wg/ml) and PRK2 (0.4 Wg/ml). Immunoblotting with
the phospho-speci¢c antibodies (0.5 Wg/ml) unless otherwise indicated
was carried out in the presence of 10 Wg/ml non-phosphorylated pep-
tide corresponding to the antigen used to raise the antibody in TBS-
Tween containing 5% (by mass) fraction-V bovine serum albumin for
16 h at 4‡C. Detection was performed using horseradish peroxidase-
conjugated secondary antibodies and the enhanced chemiluminescence
reagent (Amersham/Pharmacia). Densitometric analysis of the bands
on the autorads was carried out using the NIH Image software
(http://rsb.info.hih.gov/nih-image/).
2.8. Northern blot analysis
Total RNA was puri¢ed from PDK13/3 and PDK1+/+ ES cells
using Trizol reagent (Gibco) and mRNA subsequently isolated using
an Oligotex mRNA Mini kit (Qiagen). mRNA samples were mixed
with an equal volume of glyoxal sample bu¡er (BMA) and incubated
at 65‡C for 15 min prior to loading on a 1.25% SeaKem Gold agarose
gel (BMA). mRNA isolated from 125 Wg of total RNA was loaded in
each lane. Electrophoresis was carried out in 1UMOPS bu¡er
(200 mM MOPS, 50 mM sodium acetate, 10 mM EDTA, 10 mM
EGTA, pH 7.0). Gels were blotted onto Hybond N+ ¢lters (Amer-
sham) and the nucleic acids ¢xed on the membranes according to
standard procedures. The ¢lters were incubated in 20 mM Tris pH
8.0 for 15 min at 65‡C, to remove the glyoxal, and prehybridised for
1 h at 65‡C in ExpressHyb (Clontech). Probes were labelled by ran-
dom priming and added to ExpressHyb at 1^2U106 cps/ml and the
incubation was carried out overnight. Filters were then washed in
2USSC (30 mM sodium citrate and 0.3 M NaCl) containing 0.05%
SDS at ambient temperature for 40 min and in 0.1USSC containing
0.1% SDS for 30 min at 50‡C. Blots were exposed for 3^12 h using
Hyper¢lm MP (Amersham). After probing, the ¢lters were stripped
using boiling 1% SDS which was allowed to cool. They were then
prehybridised and probed with a L-actin probe to con¢rm similar
loading of mRNA in each gel lane. The mouse PRK1 probe corre-
sponding to amino acids 807^946 was obtained from EST clone
1380826 (accession number AI035847 obtained from the I.M.A.G.E.
consortium [13]) by digestion with EcoRI and NotI. The mouse PCKN
probe corresponding to amino acids 1^76 was obtained from EST
clone 1230613 (accession number AA879873 obtained from the
I.M.A.G.E. consortium [13]) by digestion with EcoRI and NotI.
The L-actin probe was from Clontech.
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3. Results
3.1. Reduced expression of PKC isoforms in PDK13/3 ES
cells
Cell lysates derived from PDK1+/+ or PDK13/3 ES cells
were immunoblotted with antibodies that recognise speci¢c
isoforms of PKC and the speci¢city of each antibody was
veri¢ed using a panel of recombinant PKC isoforms (Fig.
1). The cells were lysed either in a bu¡er containing Triton
X-100 or in SDS sample bu¡er to ensure solubilisation of
particulate PKC isoforms. All eight PKC isoforms that were
immunoblotted were expressed at detectable levels in the con-
trol PDK1+/+ ES cells. Although the expression of PKCj and
PRK2 is similar in PDK1+/+ and PDK13/3 ES cells, the
levels of PKCK, PKCLII, PKCQ, PKCN, PKCO and PRK1
were vastly reduced in ES cells lacking PDK1 compared to
control PDK1+/+ ES cells. The expression of PKCO and
PRK1 was virtually undetectable in PDK13/3 ES cells,
whilst PKCK, PKCLII, PKCQ and PKCN were expressed at
about 5-fold lower levels in PDK13/3 cells compared to the
control PDK1+/+ ES cells (Fig. 1). PKCLII may be the most
abundant splice variant of the PKCL isoform in ES cells as we
were unable to detect expression of PKCLI in PDK1+/+ ES
cells (data not shown). As a control, we also immunoblotted
Fig. 1. Immunoblotting of PKC isoforms in PDK13/3 and PDK1+/+ cells. PDK13/3 and PDK1+/+ ES cells cultured in the presence of
10% serum were lysed in the same volume of either bu¡er A (which contains Triton) or in SDS sample bu¡er as described in Section 2. Ali-
quots of the Triton lysate (30 Wg of protein) and the equivalent volumes of the SDS containing lysates, as well as indicated recombinant PKC
isoforms (10 ng), were subjected to SDS^polyacrylamide gel electrophoresis on a 3^8% gradient Tris acetate gel and immunoblotted with the in-
dicated PKC isoform-speci¢c antibodies. In order to detect PRK1 in extracts of Triton-lysed cells, the PDK13/3 and PDK1+/+ ES cell lysates
were incubated with protamine-agarose to bind PRK1, the beads were washed and immunoblotted with the PRK1 antibody as described in
Section 2. As a control, the cell lysates were immunoblotted for other AGC kinases (PKB, S6K1 and p90Rsk isoforms) previously shown to be
expressed at similar levels in PDK13/3 and PDK1+/+ cells. Similar results were obtained in at least four independent experiments.
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PDK13/3 and PDK1+/+ cell lysates for other AGC kinases
(PKB, S6K1 and p90Rsk isoforms) which, as reported previ-
ously [5], were expressed at similar levels in PDK13/3 and
PDK1+/+ cell lines.
3.2. Analysis of PKCN and PRK1 mRNA levels in PDK13/3
and PDK1+/+ cells
The level of expression of PKCN and PRK1 mRNA in
PDK13/3 and PDK1+/+ ES cells was investigated by North-
ern blot analysis. PKCN was expressed as a 3 kb transcript
(Fig. 2A) whilst PRK1 was expressed as a 3.5 kb transcript
similar to the sizes reported previously for these transcripts in
other cell/tissue types [14,15]. PKCN mRNA levels were mod-
erately (V50%) lower in the PDK13/3 ES cells compared to
the PDK1+/+ ES cells (Fig. 2A). In our view, this small di¡er-
ence in mRNA expression of PKCN is unlikely to account for
the V5-fold di¡erence in expression of PKCN protein in the
PDK13/3 cells compared to the PDK1+/+ ES cells. PRK1
mRNA was expressed at identical levels in PDK13/3 and
PDK1+/+ ES cells (Fig. 2B). The levels of mRNA encoding
PKCL2 and PKCO in PDK13/3 or PDK1+/+ ES cells may
be very low as we were unable to detect expression of these
PKC isoforms in Northern blotting experiments (data not
shown).
3.3. PKCj is not phosphorylated at Thr410 in PDK13/3 ES
cells
We have previously raised phospho-speci¢c antibodies that
recognise PKCj and PRK2 phosphorylated at their activation
loop, termed T410-P and T816-P, respectively [7]. In Fig. 3A,
we demonstrate that the T816-P antibody also recognised
PKCj, with far higher sensitivity than the T410-P antibody
[7]. The speci¢city of the T816-P antibody for PKCj phos-
phorylated at Thr410 was established by the demonstration
that this antibody failed to recognise a mutant form of
PKCj in which Thr410 was changed to an Ala (Fig. 1A)
and by the ¢nding that its recognition of PKCj was abolished
by preincubating the T816-P antibody with the phosphopep-
tide immunogen, but not the non-phosphorylated form of this
peptide (data not shown). For this reason, we employed the
T816-P rather than the T410-P antibody to measure phos-
phorylation of the endogenous PKCj at its T-loop in ES
cells.
It was not possible to detect phosphorylation of endoge-
nous PKCj by immunoblotting the total ES cell lysates with
the T816-P antibody. We therefore used two approaches to
purify su⁄cient PKCj from PDK13/3 and PDK1+/+ ES
cells to be able to assess its T-loop phosphorylation. The ¢rst
approach was to adsorb PKCj from the cell lysates onto
protamine-agarose, with which PKCj interacts with very
high a⁄nity. After washing with 0.5 M NaCl, the beads
were then immunoblotted with the T816-P antibody as well
as with an antibody that recognises total PKCj protein, which
runs with a molecular mass of 73 kDa distinct from that of
PRK2 (130 kDa) (Fig. 3). Although similar amounts of PKCj
were puri¢ed on protamine-agarose from both PDK13/3 and
PDK1+/+ ES cell extracts, the T816-P antibody only recog-
nised PKCj puri¢ed from PDK1+/+ cells and not from the
PDK13/3 cells (Fig. 3B).
The second approach used to purify PKCj was to fraction-
ate cell lysates by batchwise chromatography on Q-Sepharose,
followed by gradient elution from Mono S. PKCj puri¢ed
from PDK1+/+ and PDK13/3 ES cell lysates eluted as a
broad peak from Mono S at V0.5 M NaCl (see Fig. 3C).
The fractions in which PKCj eluted were immunoblotted with
the T816-P antibody which recognised only PKCj derived
from control PDK1+/+ but not from PDK13/3 cell lysates.
These ¢ndings strongly indicate that PKCj is not phosphor-
ylated at its T-loop residue in PDK13/3 cells.
3.4. Evidence that PRK2 is partially phosphorylated at its
T-loop residue in PDK13/3 ES cells
As the T816-P antibody did not recognise PRK2 in immu-
noblots of total ES cell lysates, we puri¢ed PRK2 from
PDK13/3 and PDK1+/+ ES cell extracts after their adsorp-
tion to protamine-agarose (Fig. 4A) and following its batch-
wise elution from Q-Sepharose and its chromatography on
Mono S (Fig. 4B). Immunoblotting of partially puri¢ed
PRK2 with the T816-P antibody revealed that it was signi¢-
cantly phosphorylated at its T-loop in PDK13/3 ES cells,
albeit to a V3-fold lower level than that observed in
PDK1+/+ ES cells (Fig. 4). Incubation of the T816-P anti-
body with the phosphorylated phosphopeptide immunogen
used to raise the antibody abolished its ability to recognise
PRK2 puri¢ed from both PDK13/3 and PDK1+/+ ES cells
(Fig. 4A,B), but did not a¡ect the recognition of a number of
non-speci¢c bands recognised by the T816-P antibody in the
Mono Q column fractions (Fig. 4B).
We attempted to assay PKCj and PRK2 activity in
PDK1+/+ and PDK13/3 ES cells following the immunopre-
Fig. 2. Northern blotting of PKCN and PRK1 in PDK13/3 and
PDK1+/+ cells. Partial cDNA for mouse PKCN (A) and PRK1 (B)
was labelled with 32P, using random primers, and used to probe a
Northern blot containing mRNA isolated from PDK13/3 and
PDK1+/+ ES cells. The blots were washed and autoradiographed.
The PKCN probe was observed to hybridise with a 3 kb message
and the PRK1 probe hybridised with a 3.5 kb message. The blots
were also probed with a L-actin probe as a loading control.
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cipitation of these enzymes from either ES cell lysates or from
Mono S column fractions in which ES cell lysates had been
fractionated. Although we were able to demonstrate that these
antibodies immunoprecipitated PKCj and PRK2, we were
unable to detect any signi¢cant kinase activity in the immu-
noprecipitates towards myelin basic protein, protamine sul-
phate and the peptide substrates selectide and PRK2tide
(data not shown) that we [7] and others [8,9,11,12] have pre-
viously used to assay PKCj and PRK2 expressed in transient
transfection experiments. We were also unable to measure any
signi¢cant activity of PKCj and PRK2 following the immu-
noprecipitation of these kinases from PDK1+/+ or PDK13/3
ES cells stimulated with IGF1, serum or lysophosphatidic acid
(data not shown).
4. Discussion
Conventional and novel PKC isoforms are activated by a
series of ordered phosphorylation events that are predicted to
convert these enzymes from a ‘nascent form’ to a ‘mature
form’ that still exists in an inactive conformation but which
can then become activated following interaction with diacyl-
glycerol [16,17]. The ¢rst phosphorylation event for conven-
tional PKC isoforms occurs at the T-loop residue, and is
catalysed by PDK1 [10,12]. This induces a conformational
change that enables these PKC isoforms to phosphorylate
themselves at two conserved residues lying at the carboxyl-
terminus. One of these is termed the ‘turn motif’ (Thr638 in
PKCK) and the other the ‘hydrophobic motif’ (Ser657 in
Fig. 3. PKCj is not phosphorylated at Thr410 in PDK13/3 ES cells. (A) 293 cells were transfected with constructs expressing Flag epitope-
tagged wild type PKCj (WT) or the a mutant PKCj in which Thr410 was changed to Ala (T410A) as described previously [7]. 36 h post-trans-
fection, the cells were lysed in bu¡er A, and the lysates subjected to immunoblotting with the T410-P or T816-P antibody. Short (5 s) and long
(2 min) exposures of the blots were carried out so that the relative sensitivity of the T410-P and T816-P antibodies towards PKCj could be as-
sessed. (B) PDK13/3 and PDK1+/+ ES cell lysates were incubated with protamine-agarose to bind PKCj, the beads were washed and immu-
noblotted with the T816-P antibody and an antibody that recognises PKCj (termed total PKCj) as described in Section 2. PKCj migrated
with an apparent molecular mass of 73 kDa and comigrated with recombinant Flag epitope-tagged PKCj (data not shown). (C) PDK13/3
and PDK1+/+ ES cell lysates were subjected to batchwise chromatography on Q-Sepharose, followed by a NaCl gradient elution from Mono S
as described in Section 2. The indicated column fractions (30 Wl) were immunoblotted with the T816-P antibody and the total PKCj antibody.
Similar results were obtained in three separate experiments.
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PKCK) [18]. Novel PKC isoforms are also phosphorylated at
their T-loop residue by PDK1 [12] but, while the phosphory-
lation of the ‘turn motif’ (Ser643 in PKCN) is mediated by
autophosphorylation, the hydrophobic motif (Ser662 in
PKCN) is thought to be phosphorylated by a distinct kinase(s)
[19,20]. Moreover, phosphorylation of the T-loop of novel
PKC isoforms protects the hydrophobic motif from becoming
dephosphorylated in cells [19] and therefore phosphorylation
of the hydrophobic motif of novel PKC isoforms is also de-
pendent upon phosphorylation of these enzymes at their T-
loop residue.
The observation made in this study that the levels of con-
ventional and novel PKC isoforms are vastly reduced in ES
cells lacking PDK1 (Fig. 1) indicates that the phosphorylation
of the nascent forms of conventional and novel PKC isoforms
by PDK1 plays an important role in stabilising these enzymes.
It has been suggested that the primary role that phosphory-
lation of the hydrophobic motif of conventional PKC iso-
forms plays is to stabilise these enzymes. The evidence for
this is based on the ¢nding that mutation of the phosphory-
lated Ser residue in the hydrophobic motif of conventional
PKC isoforms to Ala signi¢cantly decreases the in vitro ther-
mostability of these enzymes [21,22]. As discussed above, the
lack of phosphorylation of the T-loop of conventional and
novel isoforms of PKC in PDK13/3 ES cells would also be
expected to prevent the phosphorylation of the hydrophobic
motif of these enzymes. It is therefore possible that it is the
lack of phosphorylation of the hydrophobic motif of PKC
isoforms rather than that of the T-loop itself that accounts
for the instability of these enzymes in PDK13/3 ES cells.
The ¢nding that there is no detectable expression of PKCO
and that the expression of PKCN is greatly reduced also dem-
onstrates that phosphorylation of novel PKC isoforms by
PDK1 also plays an important role in stabilising these en-
zymes, which has previously not been reported. It should
also be noted that the expression of PKCN mRNA in
PDK13/3 cells is also moderately (V50%) reduced (Fig.
2A), indicating that PDK1 may play a minor role in regulat-
Fig. 4. PRK2 is partially phosphorylated at Thr816 in PDK13/3 ES cells. PDK13/3 and PDK1+/+ ES cell lysates were incubated with prot-
amine-agarose to bind PRK2. The beads were washed and immunoblotted with the T816-P antibody and an antibody that recognises PRK2
(termed total PRK2) as described in Section 2. PRK2 migrated with an apparent molecular mass of 130 kDa and comigrated with recombinant
Flag epitope-tagged PRK2 (data not shown). Densitometric analysis of the autorads to determine the relative intensity of PRK2 band recog-
nised by the T816-P antibody was carried out using the NIH Image software. (B) PDK13/3 and PDK1+/+ ES cell lysates were subjected to
batchwise chromatography on Q-Sepharose followed by a NaCl gradient elution from Mono S as described in Section 2. The indicated column
fractions (30 Wl) were immunoblotted with the T816-P antibody and the total PRK2 antibody. Similar results were obtained in three separate
experiments.
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ing the transcription of the PKCN gene or stabilisation of the
PKCN mRNA.
Atypical and related PKC isoforms are activated by phos-
phorylation of their T-loop, but instead of possessing a phos-
phorylatable Ser/Thr in their hydrophobic motif, they contain
an acidic residue. Recent studies, based on in vitro and over-
expression experimentation, suggest that PDK1 mediates the
phosphorylation of the T-loop motif of PKCj, PRK1 and
PRK2 [7^9,11,12]. The ¢nding in this paper, that PKCj iso-
lated from PDK13/3 ES cells is not phosphorylated at its T-
loop residue, provides the ¢rst genetic evidence that PKCj is
indeed a physiological substrate for PDK1.
Unexpectedly, PRK2 derived from PDK13/3 cells was
phosphorylated at its T-loop residue, albeit at a signi¢cantly
lower level than that observed for PRK2 puri¢ed from
PDK1+/+ ES cells (Fig. 4). Thus, in addition to being phos-
phorylated at its T-loop by PDK1, another kinase (or perhaps
PRK2 itself) could phosphorylate this site in ES cells. The
observation that expression of PRK1 in PDK13/3 cells was
virtually abolished (Fig. 1) although the mRNA levels of
PRK1 were identical in PDK13/3 and PDK1+/+ cells (Fig.
2B) was very surprising, especially as the levels of its closely
related isoform PRK2 are similar in these cells (Fig. 1). It is
possible that phosphorylation of the T-loop residue of both
PRK1 and PRK2 is required to stabilise these enzymes but
only PRK2 and not PRK1 is capable of undergoing a limited
T-loop phosphorylation in PDK13/3 cells.
In summary, this study provides the ¢rst genetic evidence
that PDK1 regulates the stability of multiple PKC isoforms in
vivo. This work supports previous biochemical studies indicat-
ing that phosphorylation of PKC isoforms plays an important
role in stabilising these enzymes.
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